ACR guidance document for safe MR practices: 2007

American Journal of Roentgenology

Volumn 188, Issue 6, 2007, Pages 1447-1474

  Kanal, Emanuel ^a   Barkovich, A James ^b   Bell, Charlotte ^c   Borgstede, James P ^d   Bradley Jr , William G ^e   Froelich, Jerry W ^f   Gilk, Tobias ^g   Gimbel, J Rod ^h   Gosbee, John ⁱ   Kuhni Kaminski, Ellisa ^a   Lester Jr , James W ^d   Nyenhuis, John ^j   Parag, Yoav ^a   Schaefer, Daniel J ^k   Sebek Scoumis, Elizabeth A ^a   Weinreb, Jeffrey ^l   Zaremba, Loren A ^m   Wilcox, Pamela ⁿ   Lucey, Leonard ⁿ   Sass, Nancy ⁿ  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of California San Diego ^*

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g MRI Planning   (United States)

^h East Tennessee Heart Consultants   (United States)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^j Purdue University   (United States)

^k GE HEALTHCARE   (United States)

^l YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

ⁿ AMERICAN COLLEGE OF RADIOLOGY   (United States)

more..

Author keywords

MR contrast agents; MRI; Safety

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE; LANTHANUM CARBONATE;

ANEURYSM CLIP; ARTICLE; ARTIFICIAL HEART PACEMAKER; CHILD SAFETY; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DOCUMENT EXAMINATION; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; FOOD AND DRUG ADMINISTRATION; HAZARD ASSESSMENT; HUMAN; IMPLANT; INTERVENTIONAL RADIOLOGY; KIDNEY DISEASE; MAGNETIC FIELD; MEDICAL DECISION MAKING; MEDICAL PERSONNEL; MEDICAL RESEARCH; MEDICAL SOCIETY; NEPHROGENIC FIBROSING DERMOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL SAFETY; PATIENT SAFETY; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RADIATION SAFETY; RADIOFREQUENCY; RADIOLOGIST; SCREENING;

EID: 34249738194     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.06.1616     Document Type: Article

References (58)

1. Chaljub G, Kramer LA, Johnson RF III, Singh H, Crow WN. Projectile cylinder accidents resulting from the presence of ferromagnetic nitrous oxide or oxygen tanks in the MR suite. AJR 2001; 177:27-30
2. ECRI hazard report. Patient death illustrates the importance of adhering to safely precautions in magnetic resonance environments. Health Devices 2001; 30:311-314
3. Kanal E, Borgstede JP, Barkovich AJ, et al. American College of Radiology white paper on MR safety. AJR 2002; 178:1335-1347
4. Kanal E, Borgstede JP, Barkovich AJ, et al. American College of Radiology while paper on MR safety: 2004 updale and revisions. AJR 2004; 182:1111-1114
5. Shellock FG, Kanal E. Policies, guidelines and recommendations for MR imaging safely and patient management. The SMRI Safely Committee. J Magn Reson Imaging 1991; 1:97-101
6. Kanal E, Shellock FG. Policies, guidelines and recommendations for MR imaging safety and patient management. The SMRI Safely Committee. J Magn Reson Imaging 1992; 2:247-248
7. Shellock FG, Kanal E. Guidelines and recommendations for MR imaging safety and patient management. III. Questionnaire for screening patients before MR procedures. The SMRI Safety Committee. J Magn Reson Imaging 1994; 4:749-751
8. American College of Radiology. ACR standard for magnetic resonance imaging monograph: safety and sedation. In: Practice guidelines and technical standards 1996. Reston, VA: American College of Radiology, 1996
9. American College of Radiology. ACR standard for performing and interpreting magnetic resonance imaging (MRI). In: Practice guidelines and technical standards 2000. Reston, VA: American College of Radiology, 2000:429-433
10. Medical Device Reporting (MDR) page. Center for Devices and Radiological Health, Food and Drug Administration Website. Available at: www.fda.gov/cdrh/ devadvice/351.html. Accessed February 6, 2007
11. U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Available at: www.fda.gov/medwatch/. Accessed February 12, 2007
12. Jarvik JG, Ramsey S. Radiographic screening for orbital foreign bodies prior to MR imaging: is it worth it? Am J Neuroradiol 2000; 21:245-247
13. Seidenwurm DJ, McDonnell CH III, Raghaven N, Breslau J. Cost utility analysis of radiographic screening for an orbital foreign body before MR imaging. Am J Neuroradiol 2000; 21:426-433
14. Kanal E, Gillen J, Evans JA, Savitz DA, Shellock FG. Survey of reproductive health among female MR workers. Radiology 1993; 187:395-399
15. American Academy of Pediatrics Committee on Drugs. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Pediatrics 1992; 89(6 Pt 1):1110-1115
16. American Academy of Pediatrics Committee on Drugs. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: addendum. Pediatrics 2002; 110:836-838
17. American Society of Anesthesiologists. Updated practice guidelines for sedation and analgesia by non-anesthesiologists. Park Ridge, IL: American Society of Anesthesiologists, 2001
18. Joint Commission on the Accreditation of Healthcare Organizations. Standards and intents for sedation and anesthesia care: comprehensive accreditation manual for hospitals. Report no. TX 2-2. Chicago, IL: JCAHO, 2002
19. Bryan YF, Templeton TW, Nick TG, Szafran M, Tung A, Brain magnetic resonance imaging increases core body temperature in sedated children. Anesth Analg 2006; 102:1674-1679
20. Gandhi OP, Chen XB. Specific absorption rates and induced current densities for an anatomy-based model of the human for exposure to time varying magnetic fields of MRI. Magn Reson Med 1999; 41:816-823
21. Konings MK, Bartels LW, Smits HFM, et al. Heating around intravascular guidewires by resonating RF waves. J Magn Reson Imaging 2000; 12:79-85
22. Shellock FG. Pocket guide to MR procedures and metallic objects: update 2001. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:147-148
23. International Electrotechnical Commission. Medical electrical equipment. Part 2. Particular requirements for the safety of magnetic resonance equipment for medical diagnosis. IEC 60601-2-33. ed. 2.0. Geneva, Switzerland: IEC, 2002. (In the United States, copies of this standard can be obtained from the American National Standards Institute (ANSI), 11 W 42nd St., New York, NY 10036.)
24. American College of Radiology. ACR practice guideline for adult sedation/analgesia. In: Practice guidelines and technical standards 2000. Reston, VA: American College of Radiology, 2000
25. American College of Radiology. ACR practice guideline for pediatric sedation/analgesia. In: Practice guidelines and technical standards 1998. Reston, VA: American College of Radiology, 1998
26. American Society of Anesthesiologists. Guidelines for non-operating room anesthetizing locations. Park Ridge, IL: American Society of Anesthesiologists, 2001
27. American Society of Anesthesiologists. Standards for basic anesthetic monitoring. Park Ridge, IL: American Society of Anesthesiologists, 1986, 1998
28. American Society of Anesthesiologists. Standards for post anesthesia care. Park Ridge, IL: American Society of Anesthesiologists, 1988, 1994
29. Joint Commission on Accreditation of Healthcare Organizations. Standards and intents for sedation and anesthesia care: comprehensive accreditation manual for hospitals. Report TX. 2-2.4.1. Chicago, IL: JCAHO, 2001
30. American College of Radiology. ACR digest of council actions. Reston, VA: ACR, 1999:126 (Res. 1-H, 1987, 1997)
31. American College of Radiology Committee on Drugs and Contrast Media. Manual on contrast media, 5.0 ed. Reston, VA: American College of Radiology, 2004
32. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108; erratum in Nephrol Dial Transplant 2006; 21:1745
33. Investigation of the safety of MRI contrast medium Omniscan, May 29, 2006. Danish Medicines Agency Website. Available at: www.dkma.dk/1024/ visUKLSArtikel.asp?artikelID=8931. Accessed January 25, 2007; last updated January 24, 2007
34. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356:1000-1001
35. Jain SM, Wesson S, Hassanein A, et al. Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 2004; 19:467-470
36. Dharnidharka VR, Wesson SK, Fennell RS. Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. (letter) Pediatr Nephrol 2006 Dec 16; [Epub ahead of print]
37. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 2007; 188:586-592
38. Maloo M, Abt P, Younan D, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006; 6:2212-2217
39. Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF Website], 2001-2007. Available at: www.icnfdr.org. Accessed January 24, 2007; site last updated January 24, 2007
40. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362
41. Thomsen HS. Nephrogenic systemic fibrosis: a serious later adverse reaction to gadodiamide. Eur Radiol 2006; 16:2619-2621
42. Khurana A, Runge VM, Narayanan M, Greene JF Jr, Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007; 42:139-145
43. White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd (HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006; 41:272-278
44. High WQ, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissues of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:21-26
45. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56:27-30
46. Idee J-M, Port M, Raynal I, Schaefer M, Greneur SL, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006; 20:563-576
47. Food and Drug Administration Center for Drug Evaluation and Research. Public health advisory. Update on magnetic resonance imaging (MRI) contrast agents containing gadolinium and nephrogenic fibrosing dermopathy. Available at: www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222.htm. Accessed February 20, 2007; last updated December 22, 2006
48. U.S. Food and Drug Administration Website. Public health advisory. Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Available at: http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Accessed August 10, 2006
49. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2001; 42:339-341
50. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5:491-502
51. Ueda J, Furukawa T, Higashino K, et al. Permeability of iodinated and MR contrast media through two types of hemodialysis membrane. Eur J Radiol 1999; 31:76-80
52. The National Kidney Foundation Kidney disease outcomes quality initiative. National Kidney Foundation Website. Available at: http://www.kidney.org/Professionals/kdoqi/. Accessed February 12, 2007
53. Centers for Disease Control and Prevention. National Center for Health Statistics Website. Third National Health and Nutrition Examination Survey (NHANES III), 1988-94. Available at: www.cdc.gov/nchs/products/elec_prods/ subject/nhanes3.htm. Accessed February 8, 2007
54. [No authors indicated] Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 2002; 39[suppl 1]:S46-S75; doi:10.1053/ajkd.2002.30943
55. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007 Jan 9 [Epub ahead of print]. Available at: http://radiology.rsnajnls.org/cgi/content/short/ 2423061640v1?rss=1. Accessed February 20, 2007
56. Medicines and Healthcare products Regulatory Agency Website. Nephrogenic systemic fibrosis (NSF) and gadolinium-containing MRI contrast agents: 7 February 2007. Available at: http://www.mhra.gov.uk/home/idcplg?IdcService= SS_GET_PAGE&useSecondary=true&ssDocName=CON2030229&ssTargetNodeId= 221. Accessed February 20, 2007
57. Thomsen HS. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 2007; 17:70-76
58. Bartsch C, Inrich W, Risse M, Weiler G. Unexpected sudden death of pacemaker patients during or shortly after magnetic resonance imaging (MRI). In: XIX Congress of International Academy of Legal Medicine. IALM: Milan, Italy, 3-6 September 2003:174 (Abstract No. 114)